Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now.

Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

A dose bottle of the medication is in the medical tech’s hand

On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

The study revealed improved event-free survival, overall survival, and pathologic complete response rates compared to surgery alone. The improved outcome was a result of giving patients KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) medicines before and after surgery.

The trial, carried out in collaboration with Pfizer and Astellas, marks the first systemic treatment that enhances survival rates in this patient group. Furthermore, no new side effects were observed.

Operating through its Pharmaceutical and Animal Health segments, Merck & Co., Inc. (NYSE:MRK) leads as a healthcare company worldwide. It is included in our list of the most undervalued value stocks to buy.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts.

Disclosure: None.